Physician profile
Daniel Tl Tan
NPI 1811193766
$247,489.45
in general payments reported to CMS, 2019-2025
30 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $33K · 2021: $22K · 2022: $24K · 2023: $33K · 2024: $35K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Honoraria: $25K · Food and Beverage: $19K · Travel and Lodging: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Consulting Fee: $1,620 · Education: $66.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,320.00 |
| Honoraria | $24,850.00 |
| Food and Beverage | $19,096.58 |
| Travel and Lodging | $11,498.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,686.75 |
| Consulting Fee | $1,620.00 |
| Education | $66.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $82,298.98 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $82,175.41 | 2019-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $42,110.83 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Noven Pharmaceuticals, INC. | $8,936.73 | 2021-2024 | Xelstrym |
| Corium, LLC | $6,473.17 | 2021-2025 | Azstarys |
| Noven Therapeutics, LLC | $3,563.71 | 2020-2025 | Xelstrym, Secuado |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,057.42 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,956.14 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $2,907.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $2,232.27 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $1,605.71 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,557.43 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Lundbeck LLC | $1,251.50 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $919.52 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $888.21 | 2020-2025 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $866.92 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $783.28 | 2022-2025 | Auvelity |
| Abbvie INC. | $700.96 | 2021-2024 | Vraylar |
| Validus Pharmaceuticals LLC | $558.40 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $348.93 | 2022-2025 | Ingrezza |
| Rhodes Pharmaceuticals L.P. | $329.44 | 2019 | |
| Indivior INC. | $263.84 | 2022-2024 | Perseris |
| Luye Pharma (USA) LTD. | $145.26 | 2025 | Erzofri Extended-Release |
| Shire North American Group INC | $142.45 | 2019 | |
| Bioxcel Therapeutics, INC. | $123.68 | 2024 | Igalmi |
| Vertical Pharmaceuticals, LLC | $113.20 | 2019-2025 | Relexxii |
| Adlon Therapeutics L.P. | $105.45 | 2019-2021 | |
| Neos Therapeutics, LP | $38.78 | 2020 | |
| Bausch Health US, LLC | $17.76 | 2022 | |
| Neuronetics, INC. | $17.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.